Researchers have mapped the global research on treatments of COVID-19

*No evidence-based effective treatment of COVID-19 currently exists, and more research is needed. These are the conclusions from an international and multidisciplinary research team, which has mapped and evaluated the global research on treatments of COVID-19. The results were published this week in the preprint server, medRxiv, which is a place where researchers can publish their results before it has been peer-reviewed.*

In a recently published research project, an international group of researchers has gathered all the existing evidence on the treatment of COVID-19, to critically evaluate which treatment works best for patients diagnosed with COVID-19.

* “No evidence-based treatment of COVID-19 currently exists. Corticosteroids seem to reduce mortality, but we still need more research to be certain about this result”, explains associate professor and head of the project, Janus Christian Jacobsen from Copenhagen Trial Unit.
* “Remdesivir is a drug that has recently showed promising results. But as more research has become available, we can now conclude that remdesivir does not reduce mortality in COVID-19 patients. The same can be concluded for hydroxychloroquine and lopinavir-ritonavir”, says Janus Christian Jakobsen.

The project will continuously include new research and update its findings, whenever new research becomes available.

* “It is essential to do this study as a living review so that we can continuously update the synthesis as more evidence becomes available. Furthermore, methodological rigor in doing this synthesis is important to ensure that the most updated and critically appraised knowledge can reach doctors, patients, and researchers as fast as possible” says the lead author of the research publication, Sophie Merrild Juul.

The international and multidisciplinary research team includes researchers from Copenhagen Trial Unit in Denmark, McMaster University in Canada, Department of Anesthesiology and Department of Infectious Diseases, Lund University Hospital in Sweden, and University of Ioannina in Greece. The primary project site is the Copenhagen Trial Unit, a centre for clinical intervention research located at Rigshospitalet, Copenhagen University Hospital.

The research project is funded by a grant from The Poul Due Jensen Foundation, the main owner of the Grundfos Group, and The Swedish Research Council.

To read the article, please visit the preprint server medRxiv website here*:* [*https://www.medrxiv.org/content/10.1101/2020.11.22.20236448v1*](https://www.medrxiv.org/content/10.1101/2020.11.22.20236448v1)

## More information

Call associate professor Janus Christian Jakobsen | phone number: 0045 2618 6242

**Facts**

**The Poul Due Jensen Foundation** is the main owner of the Grundfos Group, Denmark. Last year, the foundation donated DKK 117 million to charities and this year will donate up to DKK 200 million. In addition to the donations for clean water, sanitation and hygiene, the foundation also support initiatives fighting COVID-19.

**Copenhagen Trial Unit** (CTU) is a clinical intervention research unit at Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark conducting clinical research within all specialities. CTU collaborates with the health sectors, universities, and the industry, both in Denmark and internationally, to improve the methods of randomised clinical trials and systematic reviews of such trials. The core staff of CTU consist of experienced trialists, clinicians, epidemiologists, statisticians, information-technology engineers, and information specialists.